Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122711 | 0.92 | MAOB (0.56) | HPGDMAOBMAOANPC1RAB9A | |
| SCHEMBL30402795 | 0.88 | MAOA (0.56) | HPGDMAOBMAOAALOX5NPC1 | |
| SCHEMBL4079311 | 0.88 | MAOA (0.56) | HPGDMAOBMAOAALOX5NPC1 | |
| SCHEMBL14102978 | 0.86 | NPC1 (0.61) | HPGDMAOBNPC1RAB9AMEN1 | |
| SCHEMBL8327914 | 0.85 | MAOA (0.61) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL1564072 | 0.85 | HPGD (0.46) | HPGDMAOBMAOAALOX5RAB9A | |
| SCHEMBL1299482 | 0.85 | HPGD (0.60) | HPGDMAOBMAOANPC1RAB9A | |
| SCHEMBL23004615 | 0.84 | MAOB (0.63) | MAOBMAOAPOLBMAPT | |
| SCHEMBL15176575 | 0.84 | MAOA (0.50) | HPGDMAOBMAOAALOX5ALDH1A1 | |
| SCHEMBL1299931 | 0.84 | HPGD (0.61) | HPGDMAOBMAOAS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| WO-2021252491-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| CN-105440020-B | 1,2,3- triazole class compounds with anti-tumor activity and preparation method thereof | 常州大学 | 2018-12-18 | — | — | CN | disclosed |
| US-9447044-B2 | Thioaryl derivatives as GPR120 agonists | LG LIFE SCIENCES LTD. (KR) | 2016-09-20 | — | — | US | disclosed |
| CN-105440020-A | 1,2,3-triazole compounds with antitumor activity and preparation method for 1,2,3-triazole compounds | UNIV CHANGZHOU | 2016-03-30 | — | — | CN | disclosed |
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4235999-A | Bichromophoric benzotriazole-styrene ester ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4129723-A | Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4070339-A | Bichromophoric benzotriazole-styrene ester ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4062800-A | Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | HPGD 4005/4885MAOB 3985/4885MAOA 3798/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | HPGD 4005/4885MAOB 3985/4885MAOA 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.